Clinical Trials

21 enrolled 11 charts

CNSLymphoid

Lymphoma, Non-Hodgkin, Neuroblastoma, Central Nervous System Neoplasms

NCT01306045 2024-10-01

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

647 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

NCT01256359 2024-08-15

DOC-MEK

83 enrolled 60 charts

Melanoma

NCT02393690 2024-07-26

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

60 enrolled 12 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT02337530 2024-03-21

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

62 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT02117167 2024-01-10

SAFIR02_Lung

999 enrolled

Non-small Cell Lung Cancer Metastatic

NCT03433183 2023-12-26

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

21 enrolled

CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

NCT01248247 2022-01-12

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

334 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01160718 2019-05-15

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

46 enrolled

Breast

Breast Neoplasms

NCT01143402 2017-07-26

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

120 enrolled 8 charts

Uveal Melanoma

NCT01229150 2017-05-23

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

89 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00553332 2016-04-22

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

29 enrolled 11 charts

Bile Duct Neoplasms, Carcinoma, Hepatocellular

NCT00936221 2016-03-14

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

385 enrolled 11 charts

Melanoma

NCT00888134 2016-01-15

Selumetinib in Cancers With BRAF Mutations

28 enrolled 9 charts

Adult Solid Neoplasm

NCT01206140 2015-10-05

Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery

70 enrolled 8 charts

Sarcoma

NCT01085214 2015-08-19

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

37 enrolled 9 charts

Plasma cell

Multiple Myeloma

NCT00866177 2015-08-11

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

167 enrolled 6 charts

Melanoma

NCT00338130 2014-08-13

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

239 enrolled

Melanoma

NCT00372788 2014-08-13

AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

88 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00372944 2014-08-13

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

70 enrolled

Pancreatic Neoplasms

NCT00514761 2014-08-13

Phase II Efficacy Study of AZD6244 in Colorectal Cancer

64 enrolled

Colorectal Neoplasms

NCT00604721 2014-05-28

Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer

19 enrolled 8 charts